Sagimet Biosciences to Launch U.S. Phase 3 Trials for Acne Treatment Denifanstat

Sagimet Biosciences (NASDAQ: SGMT) has announced plans to initiate Phase 3 clinical trials in the United States for denifanstat, its primary therapeutic candidate for moderate to severe acne. The decision follows positive Phase 2 results in the U.S. and successful Phase 3 trials conducted in China by developmental partner Ascletis Bioscience. The company expects to launch the domestic Phase 3 trial in the second half of 2026. The move targets a significant market opportunity, with an estimated 10 million acne sufferers in the U.S. alone. Industry data suggests the global acne treatment market is currently valued at approximately $11 billion and is projected to grow to nearly $17 billion by 2034. To fund the next stage of clinical testing, Sagimet is raising $175 million through the issuance of over 29 million new shares priced at $6.00 per share. This capital raise represents a substantial dilution of existing equity, as the company previously had 32 million shares outstanding. Prior to the announcement, the company's market capitalization stood at just under $190 million. Beyond its lead acne candidate, Sagimet's pipeline includes TVB-3567, which is in Phase 1 trials for acne and preclinical studies for solid tumors. Additionally, the company is preparing for Phase 2 trials of denifanstat as a treatment for metabolic dysfunction associated steatohepatitis (MASH), expected to begin in the latter half of this year. Investors reacted positively to the clinical milestones, outweighing concerns over dilution. Shares of SGMT surged 45.2% following the announcement, reaching their highest valuation since November.